R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Journal ArticleDOI
Increased incidence of biliary sludge and normal gall bladder contractility in patients with high spinal cord injury
TL;DR: Patients with SCI above T10 have an increased incidence of biliary sludge and a decreased gall bladder fasting volume and Gall bladder contractility is normal as shown by normal gall bladder residual volume and emptying time.
Journal ArticleDOI
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Yingchao Zhao,Pinan Liu,Na Zhang,Jie Chen,Lukas D. Landegger,Limeng Wu,Fu Zhao,Yanxia Zhao,Yanling Zhang,Jing Zhang,Takeshi Fujita,Anat Stemmer-Rachamimov,Gino B. Ferraro,Hao Liu,Alona Muzikansky,Scott R. Plotkin,Konstantina M. Stankovic,Rakesh K. Jain,Lei Xu +18 more
TL;DR: It is shown that human NF2-associated and sporadic VSs showed significantly elevated HGF expression and cMET activation compared with normal nerves, which correlated with tumor growth and cyst formation, and CRZ treatment combined with low- dose radiation was as effective as high-dose radiation.
Journal ArticleDOI
Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis.
Rakesh K. Jain,Thomas Babcock,Teodor Burtea,Bryan Dirks,Ben Adeyi,Brian Scheckner,Robert Lasser +6 more
TL;DR: In this analysis, children with significant clinical ADHD symptoms despite MPH treatment improved during treatment with LDX and experienced similar improvements in their symptoms as the overall study population.
Journal ArticleDOI
Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype.
Vivek Rao,Neeraj Dhar,Harshavardhan Shakila,Ramandeep Singh,Aparna Khera,Rakesh K. Jain,M. Naseema,C. N. Paramasivan,P. R. Narayanan,V. D. Ramanathan,Anil K. Tyagi +10 more
TL;DR: A recombinant BCG strain is constructed producing higher levels of the 19 kDa antigen in both the cytoplasmic and extracellular fractions as compared to the wildtype BCG, resulting in complete abrogation of the protective efficacy of BCG.